Published 01-27-16
Issued by Novartis
Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at "comprehensive" level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company's performance.
Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at "comprehensive" level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company's performance.
The report is based on the results of the CR materiality analysis review conducted in 2015, which reconfirmed that access, ethics, and research and development are our most important issues. In addition, it offers insights into how Novartis manages CR, including the company's access framework, showing the variety of approaches and models used to expand access to healthcare globally.
Novartis 2015 CR highlights:
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.